266 related articles for article (PubMed ID: 34390367)
1. Early and late stage MPN patients show distinct gene expression profiles in CD34
Baumeister J; Maié T; Chatain N; Gan L; Weinbergerova B; de Toledo MAS; Eschweiler J; Maurer A; Mayer J; Kubesova B; Racil Z; Schuppert A; Costa I; Koschmieder S; Brümmendorf TH; Gezer D
Ann Hematol; 2021 Dec; 100(12):2943-2956. PubMed ID: 34390367
[TBL] [Abstract][Full Text] [Related]
2. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
3. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
4. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
5. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
6. Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators of
Zhao Y; Wang D; Liang Y; Xu C; Shi L; Tong J
Front Genet; 2022; 13():927018. PubMed ID: 36061178
[No Abstract] [Full Text] [Related]
7. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Moura LG; Tognon R; Nunes NS; Rodrigues LC; Ferreira AF; Kashima S; Covas DT; Santana M; Souto EX; Perobelli L; Simões BP; Dias-Baruffi M; Castro FA
J Clin Pathol; 2016 Oct; 69(10):926-9. PubMed ID: 27402956
[TBL] [Abstract][Full Text] [Related]
8. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
9. The Combination of
Wu S; Luo P; Rouzi T; Yu Y; Xiong B; Wang Y; Zuo X
Cancer Control; 2023; 30():10732748231163648. PubMed ID: 36895113
[TBL] [Abstract][Full Text] [Related]
10. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
11. Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells.
Guglielmelli P; Bisognin A; Saccoman C; Mannarelli C; Coppe A; Vannucchi AM; Bortoluzzi S
PLoS One; 2015; 10(10):e0140445. PubMed ID: 26468945
[TBL] [Abstract][Full Text] [Related]
12. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
13. Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.
Mora B; Passamonti F
Curr Hematol Malig Rep; 2022 Oct; 17(5):127-139. PubMed ID: 36048275
[TBL] [Abstract][Full Text] [Related]
14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
15. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
Liu L; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
[TBL] [Abstract][Full Text] [Related]
16. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
[TBL] [Abstract][Full Text] [Related]
17. [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].
Aumann K; Frey AV; May AM; Hauschke D; Kreutz C; Marx JP; Timmer J; Werner M; Pahl HL
Pathologe; 2013 Nov; 34 Suppl 2():201-9. PubMed ID: 24196613
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis.
Song J; Hussaini M; Zhang H; Shao H; Qin D; Zhang X; Ma Z; Hussnain Naqvi SM; Zhang L; Moscinski LC
Am J Clin Pathol; 2017 May; 147(5):444-452. PubMed ID: 28419183
[TBL] [Abstract][Full Text] [Related]
19. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.
Ferrer-Marín F; Arroyo AB; Bellosillo B; Cuenca EJ; Zamora L; Hernández-Rivas JM; Hernández-Boluda JC; Fernandez-Rodriguez C; Luño E; García Hernandez C; Kerguelen A; Fiallo-Suárez DV; Gómez-Casares MT; Ayala R; Vélez P; Boqué C; García-Gutierrez V; Arrizabalaga B; Estrada N; Cifuentes R; Arcas I; de Los Reyes-García AM; Besses C; Vicente V; Alvarez-Larrán A; Teruel-Montoya R; González-Conejero R; Martínez C;
Leukemia; 2020 Oct; 34(10):2648-2659. PubMed ID: 32107471
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis.
Rontauroli S; Castellano S; Guglielmelli P; Zini R; Bianchi E; Genovese E; Carretta C; Parenti S; Fantini S; Mallia S; Tavernari L; Sartini S; Mirabile M; Mannarelli C; Gesullo F; Pacilli A; Pietra D; Rumi E; Salmoiraghi S; Mora B; Villani L; Grilli A; Rosti V; Barosi G; Passamonti F; Rambaldi A; Malcovati L; Cazzola M; Bicciato S; Tagliafico E; Vannucchi AM; Manfredini R
Blood Adv; 2021 Mar; 5(5):1452-1462. PubMed ID: 33666652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]